“Ted,” a 50-year-old bicycle racer from Philadelphia, saw his primary care doctor for the last time several months ago– when he was advised to start testosterone replacement therapy. “Your labs are excellent,” said Ted’s doctor. “I’d like to frame them.” The lab values included a normal range testosterone level. Ted was there for a regular check-up and he had no particular complaints, except that he was struggling through the after-effects of a motorcycle accident.
Ted’s doctor told him that even though his testosterone level was normal, with testosterone replacement, Ted might be able to build more muscle mass and go all night. It was not as if Ted indicated he was having any trouble on either of those fronts.
“Nah, that’s okay. I don’t think I need it.” Until this episode, Ted had no real complaints about his doctor and found him pretty knowledgeable. Yet the only pamphlets that Ted saw in his doctor’s office were about testosterone. Ted suspects that his doctor, a solo practitioner, may be trying to hit a volume target: if his doctor prescribes a certain amount of testosterone replacement therapy, he may get rewarded financially by pharma in what Ted calls a “payola” type arrangement.
While the FDA has cracked down on some promotional activities, it’s still probable that doctors are rewarded for just talking up a product. The placards around the office can open a discussion that might never happen otherwise.
Ted became disgusted when he watched the front office staff ask his doctor what code to put testosterone replacement therapy under for an elderly man seen right before him. “My reaction was ‘the bucket must be pretty big if both of us are candidates for hormone replacement therapy’.”
Ad campaigns on television, newspapers, and the internet urging men age 45 and over to get screened for low testosterone and consider long-term testosterone replacement therapy (TRT) are everywhere. It is hardly surprising: hormone replacement therapy (HRT) for women was a blockbuster drug category long before randomized controlled trials went forward. It was not until the Women’s Health Initiative was stopped early because it showed a link between HRT and both cardiovascular disease and breast cancer that this trend reversed itself. The hypothesis that HRT might help avert dementia did not pan out. That marketing is far from over; journal supplements and continuing medical education programs are devoted to highlighting the limitations of the Women’s Health Initiative (for example, claiming that the women were not representative) and maximizing any studies suggesting that even a little hormone replacement therapy given with caution is not so bad after all. Now, as pharmaceutical companies take their turn with men, the marketing is proceeding ahead of rigorous scientific study.
Ads Tackle Aging, Low Libido, and Low Energy
The ads use macho imagery: cars, computers, and racing prominently. Men look moderately overweight in many ads. Some of the information on testosterone replacement on the web targets men with high cholesterol, diabetes, COPD, and asthma, suggesting that testosterone replacement therapy could reverse low libido, a bummed mood, and low energy in men age 45 and over. The catch-phrase “is it low T” appears in several Abbott ads. Abbott makes the testosterone gel AndroGel and Auxilium the testosterone gel Testim. So far, these are the two products in the US market; more are in the pipeline.
Public opinion on these ad campaigns runs the gamut of people who view it as potentially harmful disease-mongering and medicalization of aging to the point of view that testosterone could confer positive anti-aging benefits.
In June, an event was held in New York City’s Times Square, on what is known as Military Island (a military recruiting station has been there for many years), asserting that men care more about cars than they do about their health.The event featured a young race car driver, a race car, and old vintage cars. Now on the Internet, the ad plainly says it is from Abbott. The Times Square event may have been unbranded. It states that the race car driver had his testosterone checked, that it was fine, and he was relieved. if you maintain a high testosterone, you can still drive fast cars and perform like you did 20 to 40 years ago. (Too bad that the event coincided with the Anthony Weiner twitter fiasco –-hardly the optimal time for a big splash for testosterone therapy.)
One television ad shows a robust man slamming a laptop shut, walking across the screen, with the message: “Stop living life in the shadows.” An ad in the Boston Globe ran a few months back showing a healthy looking man in his forties, reading: “Has he lost that loving feeling? He may have low testosterone (lowT).” Frequently men are shown with their female partners who want the guys upstairs in the sack. The men look distracted and disinterested in sex.
In May, Pharmaceutical Executive gave Heartbeat and Auxilium Pharmaceuticals (Testim) top billing for “rich media ads that helped dispel common misunderstandings of low testosterone symptoms and increase awareness of the condition and its treatment, while keeping a sense of humor about the potentially sensitive medical issue. The unbranded ads were accompanied by the www.lowtfacts.com website and directed users to additional information on symptoms and treatment.
Some low testosterone awareness ads on the Internet that I viewed in May or June had links to the American Diabetes Association (ADA), implying that ADA must espouse the point of view that diabetes is associated with low libido, low energy, and low testosterone; hence, screening for low testosterone in men with diabetes is sensible and safe. However, such links came up empty—just bringing you to the generic ADA website. This link has since been removed, perhaps because the implication that ADA has guidelines on testosterone screening for men with diabetes is indeed a stretch.
Around the world, the United States and New Zealand are the only countries that permit DTC drug marketing, according to Barbara Mintzes, PhD, assistant professor of anesthesiology, pharmacology and therapeutics initiative, University of British Columbia, Vancouver, Canada. If you turn on television during prime time in the US, you are bound to see ads for a multitude of drugs, so much so that it is daunting. In much of the world, DTC drug marketing is illegal. Although DTC drug marketing has been illegal in Canada, the law is not enforced in Canada, Mintzes explains. “This is in part because of the large influence of US media (nearly all Canadians can see US television), and partially because of specific steps that the Canadian government has taken to re-interpret existing laws in a more permissive way,” says Mintzes. Part of this involves the definition of ‘information’ versus ‘advertising,’ another part branded ‘reminder’ ads with no health claims,” said Mintzes. “In both cases Health Canada (federal regulator) has put out advertising policy briefing papers explaining the way the law is being interpreted, and advising industry of what would and would not be considered legal,”stated Mintzes in an email. “It’s a stretch in both cases to connect what’s in those policy papers with the actual words in the law or how it was interpreted previously.”
Canada has a self-regulatory Pharmaceutical Advertising Advisory Board, which can provide opinions on direct-to-consumer ads, and report back to Health Canada. Barbara Mintzes, University of British Columbia. However, as many as 30 percent of Canadians view American television through cable and satellite.
Testosterone Promotional Marketing Questioned
In June, Mintzes and 23 physicians, researchers, and ethicists around the world, including experts at Harvard, Oxford, in Germany, Australia, lodged a formal written complaint with the Pharmaceutical Advertising Advisory Board regarding an ad campaign by Abbott in the June 6 to July 12 Globe and Mail, accompanied by a promotion to physicians, and a Canadian-based website: www.lowT.ca. The ad had been reviewed by PAAB and its logo appeared on the ad, according to Mintzes. The complaint concerns a Canadian ad. It is still pending.
The letter argues: “Not only is the message in this advertisement in contravention of the Food & Drugs Act, it has serious potential to lead to harm to public health, it provides misleading and inaccurate information that would not withstand any serious test of truth in advertising, and it is likely to lead to unjustified increases in health care costs, the latter by promoting testing of men unlikely to be suffering from hypogonadism [the technical term for having a low testosterone]. By redefining this condition to include signs of normal ageing, Abbott is promoting this product for an unapproved use – normal age-related changes in testosterone levels.”
The letter takes issue with promoting testosterone to treat lack of energy, low sex drive, loss of that loving feeling, and urging men to see their doctors for a testosterone test if they experience these things. The low T website also features a 10-question quiz that suggests complaints such as “falling asleep after dinner” or “deteriorating work performance” may be symptomatic of low testosterone.” The email to doctors suggests that 38 percent of men over age 45 could have low testosterone, which the authors contend is inflated.
Also at issue, the authors write, is targeting this to overweight men and those with diabetes, who may be at risk for heart disease. The authors point to a study in the New England Journal of Medicine of testosterone replacement therapy that was halted early because of excess cardiovascular events. (The letter did not address concerns that testosterone is ill-advised in men with prostate cancer or at elevated risk for it, but that has been a concern raised by many physicians.)
The authors of the letter to Canadian authorities also take issue with the “unbranded”campaign, which disguises that it is really from Abbott; this is not in alignment with the WHO Ethical Criteria for Medicinal Drug Promotion, signed onto by all UN Member states. The US ad campaign by Auxilium was similarly unbranded, as was the Times Square/Military Island event.
Testosterone replacement therapy could gain a foothold in markets around the world through aggressive direct to consumer drug advertising and physician incentive programs. Just like hormone replacement therapy for women, it seems to go be going forward with limited science to back broad use.
Later this week: The Science (or lack thereof) to Back Testosterone Replacement Therapy